

Longevity and Healthy Aging Technologies Market Forecasts to 2034 – Global Analysis By Technology Type (Longevity Therapeutics, Diagnostics and Biomarker Technologies, Digital Health and Monitoring Technologies, Cognitive and Mental Wellness Technologies, Aging-in-Place Technologies, and Wellness and Recovery Technologies), Product Type, Deployment Mode, Distribution Channel, Application, End User and By Geography

<https://marketpublishers.com/r/LDA16CB041A4EN.html>

Date: June 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: LDA16CB041A4EN

Abstracts

According to Statistics MRC, the Global Longevity and Healthy Aging Technologies Market is accounted for \$4.3 billion in 2026 and is expected to reach \$27.6 billion by 2034, growing at a CAGR of 26.1% during the forecast period. Longevity and Healthy Aging Technologies represent a convergent field encompassing therapeutics, diagnostics, digital health platforms, and assistive devices targeting the biological mechanisms of aging to extend healthspan and delay the onset of age-related disease. This market spans senolytic and gene therapy interventions, epigenetic reprogramming technologies, stem cell therapies, NAD+ metabolic modulators, biological age testing platforms utilizing multi-omics analysis, wearable health monitoring devices, AI-driven predictive analytics, and aging-in-place assistive systems.

Market Dynamics:

Driver:

Exponential growth in longevity science investment and breakthrough therapeutic

validations

Unprecedented venture capital and corporate investment in longevity science is translating laboratory discoveries into clinical candidates and commercially available health optimization products at an accelerating pace. Landmark research demonstrating epigenetic reprogramming, senolytics, and partial cellular rejuvenation in animal models has galvanized investor interest and established a scientific rationale for developing interventions targeting fundamental aging biology. High-net-worth individuals and sovereign wealth funds are channeling capital into longevity-focused biotechnology companies, longevity clinics, and precision diagnostics platforms, creating a virtuous cycle of investment, innovation, and market expansion that is fundamentally transforming the aging healthcare landscape.

Restraint:

Absence of validated clinical endpoints and regulatory pathways for aging as a therapeutic target

The central scientific and regulatory challenge facing longevity therapeutics is the absence of universally accepted biomarkers for aging as a clinical endpoint, complicating the design of pivotal clinical trials and regulatory submissions. The FDA currently does not recognize aging itself as a disease, limiting the direct regulatory pathway for interventions targeting biological aging mechanisms. Developing validated aging clocks and functional decline biomarkers that regulators accept as surrogate endpoints for longevity therapeutics is a foundational prerequisite for commercialization of this therapeutic category. Extended clinical trial timelines and biomarker validation requirements create lengthy capital consumption periods that challenge the financial models of early-stage longevity companies.

Opportunity:

Direct-to-consumer biological age testing and personalized longevity optimization services

The commercialization of accessible biological age testing through epigenetic clock assays, proteomics panels, and multi-omics platforms is creating a direct-to-consumer market for personalized longevity assessment and optimization programs. Longevity clinics offering comprehensive diagnostic workups combined with individualized supplementation, lifestyle, and therapeutic intervention protocols are attracting affluent

early adopters globally. As testing costs decline through sequencing technology democratization, biological age measurement is transitioning from academic research to mainstream consumer health services. Technology companies building AI-powered personalized longevity coaching platforms integrated with wearable biometric monitoring are positioned to capture large-scale consumer market share.

Threat:

Proliferation of unvalidated longevity supplements and ethical concerns around anti-aging claims

The rapid commercialization of longevity technologies has attracted a wave of nutraceutical and supplement products making unsubstantiated anti-aging claims, undermining consumer trust in the broader longevity market and attracting regulatory scrutiny. The blurry boundary between evidence-based longevity interventions and wellness marketing creates reputational risk for credible clinical-stage companies and longevity clinics adhering to rigorous scientific standards. Ethical debates around equitable access to longevity-extending technologies, potential social stratification based on lifespan, and the societal implications of dramatically extended healthspan add complexity to the regulatory and public perception environment for this emerging market.

Covid-19 Impact:

The COVID-19 pandemic amplified public awareness of the vulnerability of aging immune systems, accelerating consumer interest in proactive health optimization and longevity-focused preventive strategies. Pandemic-era health consciousness drove millions of individuals to explore biological age testing, supplement protocols, and lifestyle interventions associated with healthspan improvement. Lockdown periods provided time for personal health reflection and digital health engagement, benefitting longevity platform providers. Post-pandemic health priorities have permanently elevated interest in immune resilience, metabolic health, and aging biology, providing a sustained cultural and commercial tailwind for the longevity and healthy aging technologies market.

The Longevity Therapeutics segment is expected to be the largest during the forecast period

The longevity therapeutics segment commands the largest share within the longevity

and healthy aging technologies market, anchored by accelerating investment in senolytics, gene and cell therapies, and NAD+ metabolic modulators advancing through clinical development pipelines. Pharmaceutical companies and specialized longevity biotechs are committing substantial resources to develop interventions targeting hallmarks of aging including cellular senescence, mitochondrial dysfunction, and epigenetic dysregulation.

The Diagnostics and Biomarker Technologies segment is expected to have the highest CAGR during the forecast period

Diagnostics and biomarker technologies are projected to register the highest CAGR within the longevity market, reflecting the growing imperative to objectively measure biological aging trajectories before, during, and after therapeutic and lifestyle interventions. Epigenetic clock tests, proteomics-based biological age panels, and AI-driven multi-omics platforms are transitioning from research tools to commercial diagnostic services. As clinical trials for longevity therapeutics expand, validated biomarker technologies will become critical infrastructure for demonstrating treatment efficacy, driving institutional and biopharma adoption alongside direct-to-consumer uptake through longevity clinics and digital health platforms.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, North America holds the dominant share of the global longevity and healthy aging technologies market, reflecting the region's concentration of longevity-focused biotechnology companies, world-leading research universities, and deep venture capital infrastructure committed to funding aging biology research. The United States hosts the majority of clinical-stage longevity therapeutic developers and commercial longevity clinic networks, alongside a highly engaged affluent consumer base willing to invest in premium health optimization services.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Asia Pacific is expected to achieve the highest CAGR in the longevity and healthy aging technologies market, driven by Japan's extreme demographic aging, China's strategic national investment in biotechnology and aging research, and rapidly growing wealthy consumer segments in South Korea, Singapore, and Australia seeking premium longevity health services. Regional governments are funding aging research

consortia and creating regulatory sandboxes for longevity therapeutics.

Key players in the market

Some of the key players in Global Longevity and Healthy Aging Technologies Market include Altos Labs, Calico Life Sciences, Unity Biotechnology, Retro Biosciences, Insilico Medicine, Juvenescence, BioAge Labs, NewLimit, Life Biosciences, Rejuvenate Bio, Gero, Turn Biotechnologies, AgeX Therapeutics, Genflow Biosciences, and Oisin Biotechnologies.

Key Developments:

In March 2026, Unity Biotechnology announced the initiation of a Phase 2 clinical trial evaluating its next-generation senolytic compound in patients with age-related macular degeneration, with interim efficacy and safety readouts expected within 18 months, representing an important milestone in translating senolytic biology into clinically validated ophthalmology treatments.

In February 2026, Insilico Medicine disclosed positive Phase 1 safety data for its AI-designed longevity therapeutic candidate targeting a novel aging-associated pathway, representing one of the first AI-generated drug molecules to reach clinical evaluation in the longevity field and reinforcing the company's position as a pioneer in AI-driven aging therapeutics development.

Technology Types Covered:

Longevity Therapeutics

Diagnostics and Biomarker Technologies

Digital Health and Monitoring Technologies

Cognitive and Mental Wellness Technologies

Aging-in-Place Technologies

Wellness and Recovery Technologies

Product Types Covered:

Software Platforms

Devices and Wearables

Diagnostic Kits and Testing Services

Therapeutics and Pharmaceuticals

Nutraceuticals and Supplements

Smart Home and Assistive Devices

Robotics and Automation Systems

Deployment Modes Covered:

Cloud-Based Solutions

On-Premise Solutions

Hybrid Solutions

Distribution Channels Covered:

Direct Sales

Online Platforms

Specialty Clinics

Retail Pharmacies

Wellness Centers

E-commerce Platforms

Applications Covered:

Healthspan Extension

Preventive Healthcare

Chronic Disease Management

Neurodegenerative Disease Management

Metabolic Health Management

Mobility and Rehabilitation

Cognitive Health Enhancement

Remote Elderly Care

Personalized Wellness Management

End Users Covered:

Hospitals and Clinics

Longevity Clinics

Research Institutes and Academic Centers

Homecare Settings

Senior Living Communities

Wellness and Fitness Centers

Direct-to-Consumer Users

Insurance and Healthcare Providers

Regions Covered:

North America

United States

Canada

Mexico

Europe

United Kingdom

Germany

France

Italy

Spain

Netherlands

Belgium

Sweden

Switzerland

Poland

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Thailand

Malaysia

Singapore

Vietnam

Rest of Asia Pacific

South America

Brazil

Argentina

Colombia

Chile

Peru

Rest of South America

Rest of the World (RoW)

Middle East

Saudi Arabia

United Arab Emirates

Qatar

Israel

Rest of Middle East

Africa

South Africa

Egypt

Morocco

Rest of Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

- 1.1 Market Snapshot and Key Highlights
- 1.2 Growth Drivers, Challenges, and Opportunities
- 1.3 Competitive Landscape Overview
- 1.4 Strategic Insights and Recommendations

2 RESEARCH FRAMEWORK

- 2.1 Study Objectives and Scope
- 2.2 Stakeholder Analysis
- 2.3 Research Assumptions and Limitations
- 2.4 Research Methodology
 - 2.4.1 Data Collection (Primary and Secondary)
 - 2.4.2 Data Modeling and Estimation Techniques
 - 2.4.3 Data Validation and Triangulation
 - 2.4.4 Analytical and Forecasting Approach

3 MARKET DYNAMICS AND TREND ANALYSIS

- 3.1 Market Definition and Structure
- 3.2 Key Market Drivers
- 3.3 Market Restraints and Challenges
- 3.4 Growth Opportunities and Investment Hotspots
- 3.5 Industry Threats and Risk Assessment
- 3.6 Technology and Innovation Landscape
- 3.7 Emerging and High-Growth Markets
- 3.8 Regulatory and Policy Environment
- 3.9 Impact of COVID-19 and Recovery Outlook

4 COMPETITIVE AND STRATEGIC ASSESSMENT

- 4.1 Porter's Five Forces Analysis
 - 4.1.1 Supplier Bargaining Power
 - 4.1.2 Buyer Bargaining Power
 - 4.1.3 Threat of Substitutes
 - 4.1.4 Threat of New Entrants

- 4.1.5 Competitive Rivalry
- 4.2 Market Share Analysis of Key Players
- 4.3 Product Benchmarking and Performance Comparison

5 GLOBAL LONGEVITY AND HEALTHY AGING TECHNOLOGIES MARKET, BY TECHNOLOGY TYPE

- 5.1 Longevity Therapeutics
 - 5.1.1 Senolytics and Senotherapeutics
 - 5.1.2 Gene and Cell Therapies
 - 5.1.3 Stem Cell Therapies
 - 5.1.4 Epigenetic Reprogramming Technologies
 - 5.1.5 NAD+ and Metabolic Therapies
 - 5.1.6 Regenerative Medicine Technologies
- 5.2 Diagnostics and Biomarker Technologies
 - 5.2.1 Biological Age Testing
 - 5.2.2 Epigenetic Clocks
 - 5.2.3 Multi-Omics Platforms
 - 5.2.4 AI-Based Predictive Analytics
 - 5.2.5 Genomic and Proteomic Testing
- 5.3 Digital Health and Monitoring Technologies
- 5.4 Cognitive and Mental Wellness Technologies
- 5.5 Aging-in-Place Technologies
- 5.6 Wellness and Recovery Technologies

6 GLOBAL LONGEVITY AND HEALTHY AGING TECHNOLOGIES MARKET, BY PRODUCT TYPE

- 6.1 Software Platforms
- 6.2 Devices and Wearables
- 6.3 Diagnostic Kits and Testing Services
- 6.4 Therapeutics and Pharmaceuticals
- 6.5 Nutraceuticals and Supplements
- 6.6 Smart Home and Assistive Devices
- 6.7 Robotics and Automation Systems

7 GLOBAL LONGEVITY AND HEALTHY AGING TECHNOLOGIES MARKET, BY DEPLOYMENT MODE

- 7.1 Cloud-Based Solutions
- 7.2 On-Premise Solutions
- 7.3 Hybrid Solutions

8 GLOBAL LONGEVITY AND HEALTHY AGING TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL

- 8.1 Direct Sales
- 8.2 Online Platforms
- 8.3 Specialty Clinics
- 8.4 Retail Pharmacies
- 8.5 Wellness Centers
- 8.6 E-commerce Platforms

9 GLOBAL LONGEVITY AND HEALTHY AGING TECHNOLOGIES MARKET, BY APPLICATION

- 9.1 Healthspan Extension
- 9.2 Preventive Healthcare
- 9.3 Chronic Disease Management
- 9.4 Neurodegenerative Disease Management
- 9.5 Metabolic Health Management
- 9.6 Mobility and Rehabilitation
- 9.7 Cognitive Health Enhancement
- 9.8 Remote Elderly Care
- 9.9 Personalized Wellness Management

10 GLOBAL LONGEVITY AND HEALTHY AGING TECHNOLOGIES MARKET, BY END USER

- 10.1 Hospitals and Clinics
- 10.2 Longevity Clinics
- 10.3 Research Institutes and Academic Centers
- 10.4 Homecare Settings
- 10.5 Senior Living Communities
- 10.6 Wellness and Fitness Centers
- 10.7 Direct-to-Consumer Users
- 10.8 Insurance and Healthcare Providers

11 GLOBAL LONGEVITY AND HEALTHY AGING TECHNOLOGIES MARKET, BY GEOGRAPHY

11.1 North America

11.1.1 United States

11.1.2 Canada

11.1.3 Mexico

11.2 Europe

11.2.1 United Kingdom

11.2.2 Germany

11.2.3 France

11.2.4 Italy

11.2.5 Spain

11.2.6 Netherlands

11.2.7 Belgium

11.2.8 Sweden

11.2.9 Switzerland

11.2.10 Poland

11.2.11 Rest of Europe

11.3 Asia Pacific

11.3.1 China

11.3.2 Japan

11.3.3 India

11.3.4 South Korea

11.3.5 Australia

11.3.6 Indonesia

11.3.7 Thailand

11.3.8 Malaysia

11.3.9 Singapore

11.3.10 Vietnam

11.3.11 Rest of Asia Pacific

11.4 South America

11.4.1 Brazil

11.4.2 Argentina

11.4.3 Colombia

11.4.4 Chile

11.4.5 Peru

11.4.6 Rest of South America

11.5 Rest of the World (RoW)

- 11.5.1 Middle East
 - 11.5.1.1 Saudi Arabia
 - 11.5.1.2 United Arab Emirates
 - 11.5.1.3 Qatar
 - 11.5.1.4 Israel
 - 11.5.1.5 Rest of Middle East
- 11.5.2 Africa
 - 11.5.2.1 South Africa
 - 11.5.2.2 Egypt
 - 11.5.2.3 Morocco
 - 11.5.2.4 Rest of Africa

12 STRATEGIC MARKET INTELLIGENCE

- 12.1 Industry Value Network and Supply Chain Assessment
- 12.2 White-Space and Opportunity Mapping
- 12.3 Product Evolution and Market Life Cycle Analysis
- 12.4 Channel, Distributor, and Go-to-Market Assessment

13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES

- 13.1 Mergers and Acquisitions
- 13.2 Partnerships, Alliances, and Joint Ventures
- 13.3 New Product Launches and Certifications
- 13.4 Capacity Expansion and Investments
- 13.5 Other Strategic Initiatives

14 COMPANY PROFILES

- 14.1 Altos Labs
- 14.2 Calico Life Sciences
- 14.3 Unity Biotechnology
- 14.4 Retro Biosciences
- 14.5 Insilico Medicine
- 14.6 Juvenescence
- 14.7 BioAge Labs
- 14.8 NewLimit
- 14.9 Life Biosciences
- 14.10 Rejuvenate Bio

- 14.11 Gero
- 14.12 Turn Biotechnologies
- 14.13 AgeX Therapeutics
- 14.14 Genflow Biosciences
- 14.15 Oisin Biotechnologies

List Of Tables

LIST OF TABLES

Table 1 Global Longevity and Healthy Aging Technologies Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Longevity and Healthy Aging Technologies Market Outlook, By Technology Type (2023-2034) (\$MN)

Table 3 Global Longevity and Healthy Aging Technologies Market Outlook, By Longevity Therapeutics (2023-2034) (\$MN)

Table 4 Global Longevity and Healthy Aging Technologies Market Outlook, By Senolytics and Senotherapeutics (2023-2034) (\$MN)

Table 5 Global Longevity and Healthy Aging Technologies Market Outlook, By Gene and Cell Therapies (2023-2034) (\$MN)

Table 6 Global Longevity and Healthy Aging Technologies Market Outlook, By Stem Cell Therapies (2023-2034) (\$MN)

Table 7 Global Longevity and Healthy Aging Technologies Market Outlook, By Epigenetic Reprogramming Technologies (2023-2034) (\$MN)

Table 8 Global Longevity and Healthy Aging Technologies Market Outlook, By NAD+ and Metabolic Therapies (2023-2034) (\$MN)

Table 9 Global Longevity and Healthy Aging Technologies Market Outlook, By Regenerative Medicine Technologies (2023-2034) (\$MN)

Table 10 Global Longevity and Healthy Aging Technologies Market Outlook, By Diagnostics and Biomarker Technologies (2023-2034) (\$MN)

Table 11 Global Longevity and Healthy Aging Technologies Market Outlook, By Biological Age Testing (2023-2034) (\$MN)

Table 12 Global Longevity and Healthy Aging Technologies Market Outlook, By Epigenetic Clocks (2023-2034) (\$MN)

Table 13 Global Longevity and Healthy Aging Technologies Market Outlook, By Multi-Omics Platforms (2023-2034) (\$MN)

Table 14 Global Longevity and Healthy Aging Technologies Market Outlook, By AI-Based Predictive Analytics (2023-2034) (\$MN)

Table 15 Global Longevity and Healthy Aging Technologies Market Outlook, By Genomic and Proteomic Testing (2023-2034) (\$MN)

Table 16 Global Longevity and Healthy Aging Technologies Market Outlook, By Digital Health and Monitoring Technologies (2023-2034) (\$MN)

Table 17 Global Longevity and Healthy Aging Technologies Market Outlook, By Cognitive and Mental Wellness Technologies (2023-2034) (\$MN)

Table 18 Global Longevity and Healthy Aging Technologies Market Outlook, By Aging-

in-Place Technologies (2023-2034) (\$MN)

Table 19 Global Longevity and Healthy Aging Technologies Market Outlook, By Wellness and Recovery Technologies (2023-2034) (\$MN)

Table 20 Global Longevity and Healthy Aging Technologies Market Outlook, By Product Type (2023-2034) (\$MN)

Table 21 Global Longevity and Healthy Aging Technologies Market Outlook, By Software Platforms (2023-2034) (\$MN)

Table 22 Global Longevity and Healthy Aging Technologies Market Outlook, By Devices and Wearables (2023-2034) (\$MN)

Table 23 Global Longevity and Healthy Aging Technologies Market Outlook, By Diagnostic Kits and Testing Services (2023-2034) (\$MN)

Table 24 Global Longevity and Healthy Aging Technologies Market Outlook, By Therapeutics and Pharmaceuticals (2023-2034) (\$MN)

Table 25 Global Longevity and Healthy Aging Technologies Market Outlook, By Nutraceuticals and Supplements (2023-2034) (\$MN)

Table 26 Global Longevity and Healthy Aging Technologies Market Outlook, By Smart Home and Assistive Devices (2023-2034) (\$MN)

Table 27 Global Longevity and Healthy Aging Technologies Market Outlook, By Robotics and Automation Systems (2023-2034) (\$MN)

Table 28 Global Longevity and Healthy Aging Technologies Market Outlook, By Deployment Mode (2023-2034) (\$MN)

Table 29 Global Longevity and Healthy Aging Technologies Market Outlook, By Cloud-Based Solutions (2023-2034) (\$MN)

Table 30 Global Longevity and Healthy Aging Technologies Market Outlook, By On-Premise Solutions (2023-2034) (\$MN)

Table 31 Global Longevity and Healthy Aging Technologies Market Outlook, By Hybrid Solutions (2023-2034) (\$MN)

Table 32 Global Longevity and Healthy Aging Technologies Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 33 Global Longevity and Healthy Aging Technologies Market Outlook, By Direct Sales (2023-2034) (\$MN)

Table 34 Global Longevity and Healthy Aging Technologies Market Outlook, By Online Platforms (2023-2034) (\$MN)

Table 35 Global Longevity and Healthy Aging Technologies Market Outlook, By Specialty Clinics (2023-2034) (\$MN)

Table 36 Global Longevity and Healthy Aging Technologies Market Outlook, By Retail Pharmacies (2023-2034) (\$MN)

Table 37 Global Longevity and Healthy Aging Technologies Market Outlook, By Wellness Centers (2023-2034) (\$MN)

Table 38 Global Longevity and Healthy Aging Technologies Market Outlook, By E-commerce Platforms (2023-2034) (\$MN)

Table 39 Global Longevity and Healthy Aging Technologies Market Outlook, By Application (2023-2034) (\$MN)

Table 40 Global Longevity and Healthy Aging Technologies Market Outlook, By Healthspan Extension (2023-2034) (\$MN)

Table 41 Global Longevity and Healthy Aging Technologies Market Outlook, By Preventive Healthcare (2023-2034) (\$MN)

Table 42 Global Longevity and Healthy Aging Technologies Market Outlook, By Chronic Disease Management (2023-2034) (\$MN)

Table 43 Global Longevity and Healthy Aging Technologies Market Outlook, By Neurodegenerative Disease Management (2023-2034) (\$MN)

Table 44 Global Longevity and Healthy Aging Technologies Market Outlook, By Metabolic Health Management (2023-2034) (\$MN)

Table 45 Global Longevity and Healthy Aging Technologies Market Outlook, By Mobility and Rehabilitation (2023-2034) (\$MN)

Table 46 Global Longevity and Healthy Aging Technologies Market Outlook, By Cognitive Health Enhancement (2023-2034) (\$MN)

Table 47 Global Longevity and Healthy Aging Technologies Market Outlook, By Remote Elderly Care (2023-2034) (\$MN)

Table 48 Global Longevity and Healthy Aging Technologies Market Outlook, By Personalized Wellness Management (2023-2034) (\$MN)

Table 49 Global Longevity and Healthy Aging Technologies Market Outlook, By End User (2023-2034) (\$MN)

Table 50 Global Longevity and Healthy Aging Technologies Market Outlook, By Hospitals and Clinics (2023-2034) (\$MN)

Table 51 Global Longevity and Healthy Aging Technologies Market Outlook, By Longevity Clinics (2023-2034) (\$MN)

Table 52 Global Longevity and Healthy Aging Technologies Market Outlook, By Research Institutes and Academic Centers (2023-2034) (\$MN)

Table 53 Global Longevity and Healthy Aging Technologies Market Outlook, By Homecare Settings (2023-2034) (\$MN)

Table 54 Global Longevity and Healthy Aging Technologies Market Outlook, By Senior Living Communities (2023-2034) (\$MN)

Table 55 Global Longevity and Healthy Aging Technologies Market Outlook, By Wellness and Fitness Centers (2023-2034) (\$MN)

Table 56 Global Longevity and Healthy Aging Technologies Market Outlook, By Direct-to-Consumer Users (2023-2034) (\$MN)

Table 57 Global Longevity and Healthy Aging Technologies Market Outlook, By

Insurance and Healthcare Providers (2023-2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.

I would like to order

Product name: Longevity and Healthy Aging Technologies Market Forecasts to 2034 – Global Analysis By Technology Type (Longevity Therapeutics, Diagnostics and Biomarker Technologies, Digital Health and Monitoring Technologies, Cognitive and Mental Wellness Technologies, Aging-in-Place Technologies, and Wellness and Recovery Technologies), Product Type, Deployment Mode, Distribution Channel, Application, End User and By Geography

Product link: <https://marketpublishers.com/r/LDA16CB041A4EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LDA16CB041A4EN.html>